The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Hosted on MSN1mon
SLXN stock touches 52-week low at $0.82 amid sharp annual declineIn a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...
As of 3:07:17 PM EST. Market Open. Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ...
On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...
NEW YORK--(BUSINESS WIRE)--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers ...
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback